Notably, oncogenic SHP2 mutations (e.g., SHP2D61Y and SHP2E76K) drive CRC (HCT116 and HT-29 cell modal) progression by promoting glycolysis through nuclear translocation of PKM2, which stabilizes hnRNPK and enhances proliferation, migration, and cisplatin resistance [21]. This evidence concerns the gene PTPN11 and colorectal carcinoma.